Skip to main content

Emergent Biosolutions(EBS-N)
NYSE

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low8.01
Day High8.44
Open:8.23
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.

Top Stories: Emergent Biosolutions

Select a category then submit the form to load news
Tipranks
Emergent BioSolutions Adds Independent Director Amid Turnaround Efforts
GlobeNewswire
Emergent BioSolutions Announces Appointment of John D. Fowler, Jr. to Board of Directors
Tipranks
Emergent BioSolutions Reports Profitability Amid Ongoing Turnaround
GlobeNewswire
Emergent BioSolutions Reports Fourth Quarter and Full Year 2025 Financial Results
GlobeNewswire
Emergent BioSolutions Announces New $50 Million Stock Repurchase Program
GlobeNewswire
Emergent BioSolutions Announces Approximately $140 Million in Contract Awards with the Government of Canada, Strengthening Canada’s Leadership in Health Preparedness
GlobeNewswire
Emergent BioSolutions Receives U.S. FDA Approval of Supplemental New Drug Application (sNDA) for NARCAN® Nasal Spray Multipacks
GlobeNewswire
Emergent BioSolutions to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026
Tipranks
Emergent BioSolutions outlines transformation and financial guidance at conference
GlobeNewswire
Emergent BioSolutions Receives U.S. FDA Approval on Supplemental New Drug Application for NARCAN® Nasal Spray to be Packaged in a New Carrying Case, Making Life-Saving Naloxone More Accessible for Everyday Preparedness
Tipranks
Emergent BioSolutions Advances Turnaround With Major Debt Prepayment
GlobeNewswire
Emergent BioSolutions Announces $100 Million Paydown of Term Loan Principal, a Significant Step Achieved Toward its Multi-year Transformation
GlobeNewswire
Emergent BioSolutions Receives Delivery Order up to $21.5 Million to Supply BioThrax® (Anthrax Vaccine Adsorbed) to the U.S. Department of War in 2026
GlobeNewswire
Emergent BioSolutions and PANTHER Announce Agreement to Support the Continuation of the Africa CDC-led MpOx Study in Africa
GlobeNewswire
Emergent BioSolutions to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026
Tipranks
Emergent BioSolutions Gains FDA Approval for Winnipeg Facility
GlobeNewswire
Emergent BioSolutions Receives U.S. FDA Approval for Drug Product Manufacturing of raxibacumab at its Winnipeg, Canada Site
GlobeNewswire
Emergent BioSolutions Marks 10-Year Anniversary of the U.S. FDA Approval of NARCAN® Nasal Spray and Reinforces its Commitment to Increasing Naloxone Access
Tipranks
Emergent BioSolutions Announces Board Member Retirement
Tipranks
Analysts Have Conflicting Sentiments on These Healthcare Companies: NewAmsterdam Pharma Company (NAMS), Emergent Biosolutions (EBS) and Ginkgo Bioworks Holdings (DNA)
Tipranks
Emergent BioSolutions’ Earnings Call Highlights Strong Growth
Tipranks
Emergent BioSolutions Reports Strong Q3 2025 Results
Motley Fool
Emergent BioSolutions (EBS) Earnings Transcript
Tipranks
Emergent BioSolutions Raises Full-Year Revenue Guidance
GlobeNewswire
Emergent BioSolutions Reports Third Quarter 2025 Financial Results
GlobeNewswire
Emergent BioSolutions to Report Third Quarter 2025 Financial Results on October 29, 2025
GlobeNewswire
Emergent BioSolutions Recognizes Several Important Observances to Help Save Lives from Opioid Poisoning and Encourages Preparedness with Life-Saving Naloxone
MarketBeat
3 Small-Cap Stocks to Watch After the Fed’s Rate Cuts
GlobeNewswire
Emergent BioSolutions Secures $29 Million in MCM Product Orders from International Government Partner
Tipranks
Analysts Have Conflicting Sentiments on These Healthcare Companies: Emergent Biosolutions (EBS), Precision BioSciences (DTIL) and Kodiak Sciences (KOD)
Tipranks
Emergent BioSolutions Secures $56 Million Contract Modification
GlobeNewswire
Emergent BioSolutions Receives New Contract Modification for ACAM2000®, (Smallpox and Mpox (Vaccinia) Vaccine, Live) from the U.S. Government, Further Demonstrating Importance of Public Health Preparedness

Profile

Emergent BioSolutions, Inc. is a global specialty biopharmaceutical company offering specialized products to health care providers and governments to combat emerging public health threats. It also supplies vaccines to domestic and international non-government organizations and governments in/ outside of the U.S. BioThrax is the company's key Biodefense product, used for anthrax disease. The U.S. government is the primary purchaser of the company's Biodefense products. It supplies adjuvanted anthrax vaccine candidate, AV7909, to the U.S. government. It supplies smallpox vaccine ACAM2000, botulism therapeutic BAT, anthrax therapeutics 'raxibacumab & Anthrasil' and 3 other products to governments of different countries. It also retails 3 products Narcan nasal spray, Vaxchora and Vivoti. It provides contract development and manufacturing services to multiple pharma and biotech companies. The company has added key products Narcan nasal spray, ACAM2000, raxibacumab, Vaxchora and Vivoti through several acquisitions.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2026 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.